Ari Clinical Trials Inc is categorized under Medical Research in Redondo Beach, CA and active since 1996.
Ari Clinical Trials Inc was established in 1996, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Josef Edelstein, Executive Director at the company’s single location by writing to 520 North Prospect Avenue # 201, Redondo Beach, California CA 90277 or by phoning (310) 798-9899. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Ari Clinical Trials Inc |
| Contact Person: | Josef Edelstein, Executive Director |
| Address: | 520 North Prospect Avenue # 201, Redondo Beach, California 90277 |
| Phone Number: | (310) 798-9899 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 1996 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 6211110 |
| Share This Business: |
Ari Clinical Trials Inc was started in 1996 to provide professional Medical Research under the SIC code 8733 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Josef Edelstein, Executive Director for inquiries that concern Ari Clinical Trials Inc by calling the company number (310) 798-9899, as your correspondence is most welcome. Additionally, the physical location of the single location of Ari Clinical Trials Inc can be found at the coordinates 33.852082,-118.37895 as well as the street address 520 North Prospect Avenue # 201 in Redondo Beach, California 90277.
For its online presence, you may visit Ari Clinical Trials Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.